Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 436 publications.

La EM, Talbird SE, Kanadanian KV, Huang L, Fain J, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019 Apr 3;15(4):978-86. doi: 10.1080/21645515.2018.1556074

Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, Weinrib R, Mansfield C. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):394-403. doi: 10.1097/QAI.0000000000001945.

Khurana N, Farnham P, Hicks K, Carrico J, Sansom S. Cost-effectiveness of delivering pre-exposure prophylaxis for different HIV care-continuum levels in the United States. Poster presented at the 2019 National HIV Prevention Conference; March 20, 2019. Atlanta, GA.

Farnham P, Jacobson E, Chen Y-H, Hicks K, Sansom S. The impact of maintaining viral suppression on reducing HIV incidence: congruence of modeling results. Presented at the 2019 National HIV Prevention Conference; March 20, 2019. Atlanta, GA.

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: a cohort study of US claims database. Vaccine. 2019 Feb 21;37(9):1235-44. doi: 10.1016/j.vaccine.2018.11.079

Butler AM, Layton JB, Krueger WS, Kshirsager AV, McGrath LJ. Assessing residual bias in estimating influenza vaccine effectiveness: comparison of high-dose versus standard-dose vaccines. Med Care. 2019 Jan;57(1):73-8. doi: 10.1097/MLR.0000000000001018

Curran D, Patterson BJ, Van-Oorschot D, Buck PO, Carrico J, Hicks KA, Lee B, Yawn BP. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765-71. doi: 10.1080/21645515.2018.1558689.

Lucas A, Wilson M, Brogan AJ, Wasserman M, Jones D, Hilton B, Farkouh R. In small doses: missing the booster dose in a reduced pneumococcal conjugate vaccination schedule. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Candrilli SD, Kurosky S. Recent trends in meningococcal disease-related hospitalization in the United States. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson B, Levin M. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018 Oct 29;36(45):6810-8. doi: 10.1016/j.vaccine.2018.08.080

La EM, Talbird SE, Kanadanian KV, Fain J, Huang L, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Poster presented at the 2018 IDWeek Conference; October 4, 2018. San Francisco, CA.

Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X

McGrath LJ, Layton JB, Krueger WS, Kshirsagar AV, Butler AM. High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013. Vaccine. 2018 Oct 1;36(41):6087-94. doi: 10.1016/j.vaccine.2018.08.079

Sinha A, Meyers J, Samant S, Trantham L, Candrilli S. The incremental burden of congenital cytomegalovirus in the first year of life: a retrospective case-control analysis of Medicaid and commercial claims data. Presented at the 2018 CMV Public Health and Policy Conference; September 25, 2018. Burlington, VT.

Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Poster presented at the 2018 Congenital Cytomegalovirus (CMV) Public Health & Policy Conference; September 24, 2018. Burlington, VT.

Sacco P, Lucas A, Samant S, Sweeney C, Sinha A. Assessing the burden of congenital cytomegalovirus disease: methodology to develop a survey study of patients and caregivers in the United States. Poster presented at the Cytomegalovirus Public Health & Policy Conference 2018; September 23, 2018. Burlington, VT.

Andronis L, Oppong RA, Manga N, Senanayake E, Gopal S, Charman S, Giri R, Luckraz H. Is the Venner-PneuX endotracheal tube system a cost-effective option for post cardiac surgery care? Ann Thorac Surg. 2018 Sep;106(3):757-63. doi: 10.1016/j.athoracsur.2018.03.058

Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293

Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients on chronic hemodialysis. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug 20; 28(S2):485. doi: 10.1002/pds.4864

Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005

Khurana N, Yaylali E, Farnham PG, Hicks KA, Allaire BT, Jacobson E, Sansom SL. Impact of improved HIV care and treatment on PrEP effectiveness in the United States, 2016–2020. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):399-405. doi: 10.1097/QAI.0000000000001707

Butler AM, Layton JB, Krueger WS, Kshirsagar AV, McGrath LJ. Estimating influenza vaccine effectiveness: using an active comparator reduces bias due to confounding by frailty. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):229. doi: 10.1002/pds.4629

Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, Owino F, van der Straten A, TRIO Study Team. Young women's ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross‑over study in Kenya and South Africa. AIDS Behav. 2018 Aug;22(8):2662-73. doi: 10.1007/s10461-018-2078-5

Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.

Jacobson EU, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Effects of reaching national goals on HIV incidence, by race and ethnicity, in the United States. J Public Health Manag Pract. 2018 Jul;24(4):E1-8. doi: 10.1097/PHH.0000000000000717

Obel N, Dessau RB, Krogfelt KA, Bodilsen J, Andersen NS, Moller JK, Roed C, Omland LH, Christiansen CB, Ellermann-Eriksen S, Bangsborg JM, Hansen K, Benfield TL, Rothman KJ, Sorensen HT, Andersen NS, Lebech AM. Long term survival, health, social functioning, and education in patients with European Lyme neuroborreliosis: nationwide population based cohort study. BMJ. 2018 May 30;361:k1998. doi: 10.1136/bmj.k1998

Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.

Lucas A, Wilson M, Wasserman M, Jones D, Vyse A, Slack M, Hilton B, Madhava H, Farkouh R. Dynamic transmission modeling of pneumococcal conjugate vaccine and potential dosing reduction in the United Kingdom. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 17, 2018. Melbourne, Australia.

Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.

Buck PO, Curran D, Patterson BJ, Varghese L, Van Oorschot D, Carrico J, Hicks K, Lee BY, Yawn BP. Cost-effectiveness of adjuvanted recombinant zoster vaccine (RZV) for vaccinating US adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.

Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, Van Oorschot D, Lee B, Yawn B. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and postherpetic neuralgia case avoidance in the United States for people previously vaccinated against HZ. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the American Society Health System Pharmacist (ASHP) Conference.

Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, Van Oorschot D, Lee B, Yawn B. Assessment of the potential herpes zoster and postherpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the IDWeek 2017 Conference.

van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, Owino F, Schwartz J, Minnis A, TRIO Study Team. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018 Mar;21(3):e25094. doi: 10.1002/jia2.25094

Schelfhout J, Jiang Y, Miles L, Merchant S, Graham J. Cost effectiveness of letermovir as cytomegalovirus prophylaxis in in allogeneic hematopoietic stem cell transplant recipients. Poster presented at the 2018 BMT Tandem Meetings; February 2018. Salt Lake City, UT. [abstract] Biol Blood Marrow Transplant. 2018 Mar; 24(3 Supplement):S384. doi: 10.1016/j.bbmt.2017.12.473

Weinrib R, Minnis A, Agot KA, Ahmed K, Owino F, Manenzhe K, Cheng H, van der Straten A. End-users' product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018 Jan;22(1):133-45. doi: 10.1007/s10461-017-1911-6

Patterson BJ, Buck PO, Carrico J, Hicks K, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and post herpetic neuralgia case avoidance in the US for people previously vaccinated against HZ. Poster presented at the American Society Health System Pharmacist (ASHP) Midyear Clinical Meeting and Exhibition; December 5, 2017. Orlando, FL.

Candrilli S, Trantham L. Recent trends in congenital cytomegalovirus-related hospitalization in the United States. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.

Graham J, Talbird SE, Monsanto H, Perez Bolde-Villareal C, Daniels V, Pillsbury M, Wolfson LJ. Budget impact of a one-dose varicella vaccination program using outputs of a dynamic transmission model: Mexican national perspective. Poster presented at the 17th Annual Congress of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE); November 2017. Cancun, Mexico.

McInerney KA, Hatch EE, Wesselink AK, Mikkelsen EM, Rothman KJ, Perkins RB, Wise LA. The effect of vaccination against human papillomavirus on fecundability. Paediatr Perinat Epidemiol. 2017 Nov;31(6):531-6. doi: 10.1111/ppe.12408

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144

Hutchinson AB, Hicks KA, Carrico J, Sansom SL. Cost-effectiveness of screening high-risk heterosexuals for HIV in the United States. Poster presented at the 39th Annual Society for Medical Decision Making Annual North American Meeting; October 24, 2017. Pittsburgh, PA.

Patterson BJ, Buck PO, Carrico J, Hicks KA, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Assessment of the potential herpes zoster and post herpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.

Nance R, Vannappagari V, Johannes C, Calingaert B, Saltus C, Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095

Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.

Rausch D, Levin MJ, Meyers JL, Candrilli SD, Yan S, Krishnarajah G, Patterson B. Cost of herpes zoster and related complications in patients with immunocompromising conditions aged ≥50 years: a US insurance claims data analysis. Presented at the AAFP Family Medicine Experience; September 2017. San Antonio, TX.

Johannes C, Beachler D, Ziemiecki R, Yin R, McGrath L, Jemison J, Lanes S, Gilsenan A. Characteristics of new users of dapagliflozin and other antidiabetic drugs: United States and United Kingdom. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):129. doi: 10.1002/pds

Montgomery E, Atujuna M, Ndwayana S, Krogstad E, Hartmann M, Weinrib R, Bekker L-G, Minnis A. The invisible product: preferences for long-acting injectable and implantable PrEP among South African youth. Poster presented at the 9th IAS Conference on HIV Science 2017; July 23, 2017. Paris, France.

Minnis A, Roberts S, Agot K, Weinrib R, Ahmed K, Manenzhe K, Owino F, van der Straten A, Trio StudyGroup. End-user research on multipurpose prevention technologies (MPT) for HIV and pregnancy prevention: young women's ratings of three delivery forms in a randomized, cross-over study in Kenya and South Africa. Poster presented at the 9th IAS Conference on HIV Science 2017; July 23, 2017. Paris, France.